MSD has expanded its presence in Ireland with an agreement to buy a vaccine manufacturing facility from Chinese biotech WuXi Biologics for around €500 million (around $520 million). The plant in ...
For now, her focus is on making the most of its existing portfolio, notably Keytruda – the world’s top-selling cancer drug – ...
Hosted on MSN1mon
MSD acquires WuXi's vaccine facility in Dundalk for €500mChina's WuXi Biologics is to sell its vaccine manufacturing site in Dundalk to MSD Ireland in a €500m deal. The acquisition is expected to be completed in the first half of this year and will ...
Hosted on MSN1mon
WuXi Biologics to sell Ireland-based vaccine site to MSD for $500mWuXi Biologics subsidiary WuXi Vaccines has agreed to sell its vaccine manufacturing facility in Dundalk, Ireland, to MSD for approximately $500m. Expected to close in the first half of 2025 ...
In 2017, MSD made the decision to open a ... this year it had decided to build a $360 million manufacturing facility in the Republic of Ireland instead of the UK, blaming the tax burden imposed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback